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S UMM A R Y
OB J E C T I V E : To characterise childhood tuberculosis
(TB) treated with second-line drugs (SLDs) in Lima,
Peru.
DE S I GN : Results for the age groups ,5 and 5–14 years
were compared and treatment outcomes were assessed in
cases reported between 2011 and 2015 from six districts
of Lima.
R E SU LT S : Of 96 reported cases, 82 were evaluated.
Among these, 59% were boys; the median age was 8
years and 32% were aged ,5 years. Contact with a TB
case was reported in 82% of cases; 90% were treatment-
naı¨ve, 98% had pulmonary localisation and 50%
underwent the tuberculin skin test (purified protein
derivative), with induration710 mm in 88%. A positive
smear was found in 40%, all in the 5–14 years age
group, and 46% were culture-positive. Only 26% had
confirmed multidrug-resistant TB, 90% of whom were
in the 5–14 years age group. SLDs for confirmed or
probable drug-resistant TB (DR-TB) were administered
to all cases, with a high proportion of success (over
83%), no failures or deaths and a high proportion of loss
to follow-up.
CONC LU S I ON : The main indication for SLDs in child-
hood TB was the empirical treatment of DR-TB due to
contact with one or more identified DR-TB patients.
Bacteriological confirmation was limited; however,
treatment success was adequate.
K E Y WORD S : children TB; SLDs; treatment outcome;
MDR-TB; multidrug-resistant tuberculosis
ALTHOUGH THE ACTUAL RATE of childhood
tuberculosis (TB) is not known, in 2016 the World
Health Organization (WHO) estimated that there
were 1 million new cases of childhood TB, accounting
for about 6.9% of all estimated new cases world-
wide.1 Estimation of drug-resistant TB (DR-TB) in
children is limited because bacteriological confirma-
tion of drug resistance in childhood TB cases is
difficult; it has nevertheless been estimated that 15%
of multidrug-resistant TB (MDR-TB) cases occur in
children aged ,15 years.2 Small children develop
paucibacillary or extra-pulmonary TB, they cannot
expectorate and this limits TB bacteriological confir-
mation; physicians are thus forced to base their
diagnosis on a number of criteria, the most important
of which are the clinical picture, history of contact
(epidemiological), tuberculin reaction and imaging or
histopathology studies.3 Due to the limitations in
confirming DR-TB in children, treatment is often
based on the resistance profile of the index case, who
is usually an adult in the family.4
In Peru, of the 30 000 TB cases reported in 2014,
7.7% were childhood TB, 54% of whom had
negative smear or no bacilloscopy. It was estimated
that 3–5% of childhood forms were MDR-TB and
were treated with second-line drugs (SLDs).5,6 Other
treatment indications for SLDs in children are
isoniazid (INH) resistant TB without MDR-TB, and
severe adverse reactions (ADRs) to first-line drugs.
Programmatically, treatment response in children
who receive SLDs is not monitored, and the
dimension of bacteriological confirmation or the
clinical-epidemiological profile of these childhood
TB cases is not known.
The objective of the present study was to describe
the clinical-epidemiological characteristics and treat-
ment outcomes of childhood TB patients treated with
SLDs in six districts, diagnosed between 2011 and
2015 in Eastern Lima, Peru, where the DR-TB rate is
the highest in the country.
MATERIALS
This was an operational research study using a
retrospective cohort design.
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Study site
The study was conducted in the Lima Este Metro-
politan Network of the Ministerio de Salud (MIN-
SA). It comprises the six districts (population
approximately 1 554 000) of El Agustino, Santa
Anita, Ate, Lurigancho-Chosica, Cieneguilla y Cha-
clacayo. Since 2008, MINSA has gradually imple-
mented universal access to MDR-TB diagnosis using
rapid tests endorsed by the World Health Organiza-
tion (WHO), such as the microscopic-observation
drug susceptibility (MODS) assay, GenoTypew
MTBDRplus (Hain Lifescience, Nehren, Germany)
and the nitrate reductase assay (Griess test).7,8
Contact investigation is mandatory for all household
members and close contacts of the index case outside
the home, independent of age or human immunode-
ficiency virus (HIV) status. The diagnosis of paediat-
ric cases is based on clinical, epidemiological (TB
contact identification), microbiological (smear and
culture, not molecular testing), immunological (tu-
berculin skin test), radiological (X-ray and computed
tomography) and histopathological criteria. Cases
that are difficult to diagnose are referred to paediatric
pulmonologists in regional hospitals. Diagnosis and
treatment of susceptible and resistant TB are free of
charge for the patient and administered on an out-
patient basis at primary health care sites. The
duration and composition of the treatment regimens
are based on the 2011 WHO guidelines for DR-TB
treatment.9
Study population
Patients aged ,15 years notified with a TB diagnosis
and started on treatment with SLDs between 2011
and 2015 were identified from the Electronic Medical
Records (EMRs) of Peru’s MINSA National Pro-
gramme for Tuberculosis Prevention and Control.
Patients were excluded if their clinical records and
treatment cards could not be retrieved from the health
care sites where they were treated or if they did not
belong to the Lima Este Metropolitan Network.
Data collection
During the first quarter of 2016, 36 health care sites
where children received treatment were visited by one
of the authors. Clinical records, treatment cards and
TB case registers were reviewed; data were collected
in a previously validated questionnaire containing the
variables age, date of birth, district of origin, date of
TB diagnosis, date of DR-TB diagnosis, treatment
initiation, history of contact at home and its
characteristics, DR-TB contacts and patient resis-
tance profile, complementary tests, indications for
treatment with SLDs, drugs administered, treatment
outcomes and reason for discontinuing the regimen.
Data regarding ADRs were not collected due to the
high probability of underreporting in medical re-
cords.
Statistical analysis
Epidemiological and clinical characteristics were
compared between patients aged ,5 and those aged
5–14 years. A v2 test or Fisher’s exact test was used to
assess the difference between categorical variables. P
, 0.05 was considered statistically significant. The
database was created using Epi Infoe 7.0 (Centers for
Disease Control and Prevention, Atlanta, GA, USA)
and was analysed using Stata v14 (StataCorp, College
Station, TX, USA).
Ethical considerations
The study protocol was approved by the Ethics
Committee at the Hospital Nacional Hipo´lito Un-
anue, Lima Este, Peru, and the Ethics Advisory Group
of the International Union Against Tuberculosis and
Lung Disease (The Union), Paris, France.
RESULTS
Using the EMR, 96 children with the screening
criteria were identified, 14 of whom were excluded
from the analysis: five were from a different district
and in nine the clinical records could not be retrieved.
The evaluated population comprised 48 males (59%)
and 34 females (41%). The median age was 8 years,
with an interquartile range (IQR) of 4–12 years for
the overall group; the median age was 8.5 years in
boys (IQR 3–12) and 8 years in girls (IQR 4–12).
Tables 1 and 2 show the main clinical and epidemi-
ological characteristics of the population, and com-
pare the 26 (32%) children aged,5 years with the 56
(68%) children aged 5–14 years.
Of the study population, 80% came from three
districts: El Agustino, Santa Anita and Ate. In 67
cases of childhood TB, at least one contact with TB
was identified; of these, 63 cases (94%) had contacts
at home, 30 of whom (48%) had two or more
contacts with TB. The most common relations were
mother and uncle. Of the 99 TB cases identified
among contacts, 51% had MDR-TB and 15%
extensively drug-resistant TB (XDR-TB), with no
significant differences between the two age groups
(Table 1). Most children aged,5 years were detected
through contact investigation (73%), while children
aged 5–14 years were identified through out-patient
visits (75%): this difference was statistically signifi-
cant (P , 0.001).
In the 5–14 years age group, 52% started treatment
with first-line drugs and then switched to SLDs after
drug susceptibility testing (DST) results became
available, while a significantly higher proportion of
children aged ,5 years (77%) were treated with
SLDs from the start (P , 0.004). Treatment was
started for confirmed MDR-TB disease in 26% of
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patients, in 57% for probable DR-TB, in 10% for
resistance to INH, and in 7% due to a regimen change
caused by ADRs or other reasons. Among children
aged ,5 years, 88% were initiated on SLDs due to
probable DR-TB and 8% due to confirmed MDR-TB;
this was significantly different from the 5–14 years
age group (respectively 43% and 34%). In 55% of
cases, no DST was performed; the treatment regimen
was based solely on the index case’s regimen, except
for cases who were admitted with an ADR. Among
the 37 patients with DST results, 34 (92%) belonged
to the 5–14 years age group; 60% had MDR-TB and
23% were INH-resistant; 34% were detected using
rapid assays (MTBDRplus, MODS and Griess) and
the rest using the proportion method. The overall test
results showed 78% with resistance to INH, 57% to
rifampicin, 60% to streptomycin, 60% to pyrazin-
amide and 32% to ethambutol.
More patients in the 5–14 years age group had
clinical manifestations (84%) than in the under 5
group (50%). The most common symptoms were
cough, weight loss and appetite loss, and differed
significantly between the two groups (Figure 1). The
most commonly used criteria for diagnosis in children
aged,5 years were radiological, epidemiological and
immunological (Figure 2).
At the time of evaluation, 22 patients were still on
treatment. Among the 60 patients with treatment
results, 14 (23%) had confirmed MDR-TB, 34 (57%)
probable DR-TB (contact with a DR-TB index case),
8 (13%) were INH-resistant but not MDR-TB and 4
(7%) were treated for ADRs (Table 3). Treatment
success was high, at between 83% and 100%; 11–
17% of patients were lost to follow-up, and there
were no failures or deaths. The treatment regimen
was not changed in any of the cases due to ADRs.
Figure 3 shows the drugs used according to the type of
diagnosis (confirmed or probable DR-TB). Only
drugs from WHO Groups 1–4 were used, according
to the 2011 WHO guidelines for DR-TB treatment.9
DISCUSSION
This report presents the epidemiological and clinical
characteristics of childhood TB treated programmat-
ically with SLDs in a high MDR-TB prevalence area
in Lima. Of note are the limitations in TB bacterio-
logical diagnosis and TB drug resistance detection in
this population; however, we report a high treatment
success rate, which is consistent with other studies
from Peru and other developing countries.4,10
Most children aged ,5 years were identified by
contact investigation (96%), consistent with interna-
tional evidence,11,12 while 75% of cases in the 5–14
years age group were detected on consultation for
active disease. This finding suggests limitations in the
study of TB contacts in this age group, given that
contact investigation of all household contacts is
Table 1 Epidemiological characteristics of children with TB treated with second-line drugs in
Lima Este, Peru, 2011–2015
Characteristics
0–4 years
(n ¼ 26)
n (%)
5–14 years
(n ¼ 56)
n (%)
Total
(n ¼ 82)
n (%) P value*
Male sex 16 (62) 32 (57) 48 (59) 0.7
History of TB household contact 25 (96) 38 (68) 63 (77) 0.018
History of TB contact outside the home 0 4 (7) 4 (5)
Two or more TB contacts in the home† 10 (40) 20 (53) 30 (48) 0.34
Relationship with the most likely index case‡ 0.97
Mother 8 (32) 15 (39) 23 (37)
Uncle 9 (36) 14 (37) 23 (37)
Father 4 (16) 6 (16) 10 (16)
Sibling 3 (12) 4 (11) 7 (11)
Other 1 (4) 3 (8) 4 (6)
Profile of DR-TB contacts identified (n ¼ 99)§ 0.48
MDR-TB 13 (52) 21 (50) 48 (51)
XDR-TB 2 (8) 8 (19) 12 (15)
Other DR-TB, non-MDR-TB 8 (32) 12 (29) 30 (30)
Not specified 2 (8) 1 (2) 9 (4)
BCG scar present 20 (77) 36 (64) 56 (68) 0.38
Previous treatment history 0.22
Never treated 25 (96) 49 (88) 74 (90)
Previously treated 1 (4) 7 (12) 8 (10)
Case detection process ,0.001
Out-patient visit 7 (27) 42 (75) 49 (60)
Contact study 19 (73) 14 (25) 33 (40)
*v2 test.
† Percentage of 63 cases with a TB contact case at home.
‡ Percentage of 25 and 38 household contacts, respectively.
§ Percentage of the 99 TB index cases identified.
TB¼ tuberculosis; DR-TB¼ drug-resistant TB; MDR-TB¼multidrug-resistant TB; BCG¼ bacille Calmette-Gue´rin.
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Table 2 Clinical characteristics of children with TB treated with second-line drugs in Lima Este,
Peru, 2011–2015
Characteristics
0–4 years
(n ¼ 26)
n (%)
5–14 years
(n ¼ 56)
n (%)
Total
(n ¼ 82)
n (%) P value*
Nutritional status 0.25
Well nourished 23 (88) 41 (73) 64 (78)
Acute malnutrition 3 (12) 13 (23) 16 (20)
Chronic malnutrition 0 2 (4) 2 (2)
PPDs performed 22 (85) 19 (34) 41 (50) ,0.001
PPD 710 mm 20 (77) 16 (29) 36 (44) 0.51
Sputum smear test 2 (8) 48 (86) 50 (61) ,0.001
Negative 2 (100) 15 (31) 17 (34)
Paucibacillary 0 2 (4) 2 (4)
AFBþ 0 13 (27) 13 (26)
AFBþþ 0 3 (6) 3 (6)
AFBþþþ 0 15 (31) 15 (30)
Gastric aspirate culture 21 (81) 8 (14) 29 (35) ,0.001
Negative 18 (86) 8 (100) 26 (90) 0.73*
Positive 3 (14) 0 (0) 3 (10)
Sputum culture 23 (88) 56 (100) 79 (96) 0.06
Positive 1 (4) 37 (66) 38 (46) ,0.001
TB localisation 0.54*
Pulmonary 25 (96) 55 (98) 79 (96)
Extra-pulmonary 1 (4) 1 (2) 2 (2)
On SLDs since initiation 20 (77) 27 (48) 47 (57) ,0.004
Reason for SLD initiation
Probable DR-TB disease 23 (88) 24 (43) 47 (57) ,0.001
Confirmed MDR-TB disease 2 (8) 19 (34) 21 (26) 0.011
Confirmed INH-resistant, non-MDR disease 1 (4) 7 (13) 8 (10) 0.209*
Adverse drug reactions 0 4 (7) 4 (5) 0.210*
Other reasons 0 2 (4) 2 (2) 0.462*
Hospitalisation during treatment 2 (8) 10 (18) 12 (15) 0.193*
Patients with DST results 3 (12) 34 (61) 37 (45) ,0.001
Classification based on child susceptibility pattern 0.86
MDR-TB 2 (67) 19 (59) 21 (60)
INH-resistant TB, without MDR-TB 1 (33) 7 (22) 8 (23)
Pansusceptible 0 5 (16) 5 (14)
Polyresistant TB 0 2 (6) 2 (5)
Other resistance 0 1(3) 1(3)
* Fisher’s exact test; the remaining P values were calculated using the v2 test.
TB ¼ tuberculosis; PPD ¼ purified protein derivative; AFB ¼ acid-fast bacilli; SLD ¼ second-line drugs; DR-TB ¼ drug-
resistant TB; MDR-TB¼multidrug-resistant TB; DST¼ drug susceptibility testing; INH¼ isoniazid.
Figure 1 Clinical manifestations observed in patients at the time of TB diagnosis in children
treated with second-line drugs in Lima Este, Peru, 2011–2015. *The difference between groups is
statistically significant (P , 0.05). TB¼ tuberculosis.
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mandatory in Peru. The identification of two or more
contacts with TB (index cases) in the family in a large
proportion of children reveals a high risk of
tuberculous infection among families in this area of
Lima. Purified protein derivative (PPD) testing was
used in only 50% of cases, as it is not generally
available in Lima or worldwide;13 likewise, the
absence of bacille Calmette-Gue´rin scarring in 32%
of cases calls for a review of strategies used for
vaccination coverage at birth in Peru. The use and
efficacy of nasogastric aspirate were limited, and
sputum induction was not used. Both methods, if
used adequately, have shown merit in childhood TB
detection, and are compatible with molecular tests
such as the Xpertw MTB/RIF test (Cepheid, Sunny-
vale, CA, USA), which has been endorsed by the
WHO for diagnostic use in childhood TB.14–16 Peru is
one of the countries that benefit from subsidised
Xpert equipment and cartridge prices; however, the
real costs through the local distributor are still high,
and there are many bureaucratic barriers to buying
them with public funds. This is a task pending for the
national authorities.
As expected, most children aged ,5 years started
empirical treatment for MDR-TB based on the
diagnosis of their index case. In this age group, up
to 46% of patients did not report any symptom, and
given the similarities between TB symptoms and
other common childhood diseases, such as asthma,
bronchial obstruction syndrome and malnutrition,
TB may have been overdiagnosed. Conversely, in the
5–14 years age group, clinical manifestations of the
disease were present in 84% of cases. Radiology was
a defining element in 100% of cases, and this finding
confirms the importance of this test in paediatric
populations; limitations stem from the need for a
specialised radiologist or pulmonologist who can
correctly read images (X-ray and computed tomog-
raphy).
A high treatment success rate was seen in patients
with confirmed MDR-TB or probable DR-TB using
regimens based on Groups 1–4 of the WHO’s 2011
update.9 In Chiang et al.’s study conducted in Peru,
the treatment success rate was 77.2%; however,
children had a significantly higher risk of treatment
failure or death if they had severe disease or were
underweight.4 In our study, there were no severe
cases, and children with some degree of malnutrition
showed favourable evolution, as reported previous-
ly.10,11,17
Study limitations included the use of EMRs as the
main source of information, which led to incomplete
data reports using different formats, despite being
part of the same health care network. Patients were
Figure 2 Criteria used for TB diagnosis in children treated with second-line drugs in Lima Este,
Peru, 2011–2015. *The difference between the groups is statistically significant (P , 0.05).
†Tuberculin skin test; ‡TB-associated manifestations.
Table 3 TB treatment outcome in children aged ,15 years treated with second-line drugs according to type of diagnosis
Probable DR-TB Confirmed MDR-TB MDR-TB Isoniazid-resistant ADRs
,5 years
n (%)
5–14 years
n (%)
,5 years
n (%)
5–14 years
n (%)
Total
n (%)
,5 years
n (%)
5–14 years
n (%)
,5 years
n (%)
5–14 years
n (%)
Cases, n 18 16 2 12 14 1 7 0 4
Success 16 (89) 14 (88) 2 (100) 10 (83) 12 (86) 1 (100) 6 (86) 0 4 (100)
Cured 14 (78) 12 (74) 1 (50) 9 (75) 10 (72) 0 6 (86) 0 3 (75)
Completed treatment 2 (11) 2 (13) 1 (50) 1 (8) 2 (14) 1 (100) 0 0 1 (25)
Lost to follow-up 2 (11) 2 (13) 0 2 (17) 2 (14) 0 1 (14) 0 0
Failure 0 0 0 0 0 0 0 0 0
Death 0 0 0 0 0 0 0 0 0
TB¼ tuberculosis; DR-TB¼ drug-resistant TB; MDR-TB¼multidrug-resistant TB; ADR¼ adverse drug reactions.
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excluded if EMRs could not be retrieved or informa-
tion was too limited. We do not know if this exclusion
created a bias, as we did not have access to
information about these patients. Not being able to
assess the frequency of ADRs was another limitation.
Despite the limitations faced by the facilities where
the study was conducted, treatment success results
were encouraging, and testified to the effort made by
health care professionals to achieve treatment com-
pletion in each patient.
Figure 3 Drugs used to treat TB in children aged ,15 years according to type of prescription.
MDR-TB¼multidrug-resistant tuberculosis; DR-TB¼ drug-resistant TB; PZA¼ pyrazinamide; CS¼
cycloserine; ETH¼ethionamide; EMB¼ethambutol; LVX¼ levofloxacin; PAS¼para-aminosalicylic
acid; MFX ¼ moxifloxacin; CPM ¼ capreomycin; CFX ¼ ciprofloxacin; Amx/Clv ¼ amoxicillin/
clavulanic acid; RMP¼ rifampicin; KM¼ kanamycin; INH¼ isoniazid; SM¼ streptomycin; AMK¼
amikacin.
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In our opinion, the implications of this report for
Peru’s public health system (and possibly for a
number industrialised countries as well) include the
need to establish better sampling techniques, making
gastric aspirates, sputum induction and other sam-
ples, such as faeces, more accessible. Molecular
methods, such as Xpert for samples from children
and liquid culture, should be introduced to reduce the
use of empirical treatment. Treatment duration
should be reduced using the new, shorter WHO
regimen for MDR-TB recommended for children, and
avoiding injectable drugs for MDR-TB cases with
non-severe disease18 to reduce the 12% dropout rate
reported in this study and the possibility of ADRs.
Finally, new MDR-TB drugs such as delamanid,
which has already been approved for use in paediatric
populations, should be introduced promptly.19
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R E´ S U M E´
OB J E C T I F : Caracte´riser la tuberculose (TB) de l’enfant
traite´e par des me´dicaments de deuxie`me ligne (SLD) a`
Lima, Pe´rou.
S CH E´MA : Cas rapporte´s entre 2011 et 2015 dans six
districts de Lima. Les re´sultats relatifs aux groupes d’aˆge
,5 ans et entre 5 et 14 ans ont e´te´ compare´s et les
re´sultats du traitement ont e´te´ e´value´s.
R E´ S U LTAT S : Sur 96 cas rapporte´s, 82 ont e´te´ e´value´s.
Parmi eux, 59% ont e´te´ des garc¸ons, d’aˆge me´dian 8 ans,
et 32% e´taient aˆge´s de,5 ans. Un contact avec un cas de
TB a e´te´ rapporte´ dans 82% des cas. Quatre-vingt-dix
pour cent n’avaient jamais e´te´ traite´s, 98% avaient une
localisation pulmonaire et 50% ont eu un test cutane´ a` la
tuberculine (de´rive´ prote´inique purifie´), avec une
re´action de 710 mm chez 88%. Un frottis positif a e´te´
constate´ chez 40% des enfants, tous dans le groupe d’aˆge
5 a` 14 ans et 46% ont eu une culture positive. Seulement
26% ont eu une confirmation de TB multire´sistante,
dont 90% dans le groupe d’aˆge de 5 a` 14 ans. Les SLD
pour une TB confirme´e ou probablement
pharmacore´sistante (DR) ont e´te´ administre´s a` tous les
cas, avec une proportion e´leve´e de succe`s (plus de 83%),
sans cas d’e´chec ni de de´ce`s et une proportion e´leve´e de
perdus de vue.
CONC LU S I ON : L’indication principale des SLD dans la
TB de l’enfant a e´te´ le traitement empirique de la TB-DR
due a` un contact avec un ou plusieurs patients TB-DR
identifie´s. La confirmation bacte´riologique a e´te´ limite´e,
mais le taux de succe`s du traitement a e´te´ suffisant.
R E S UM E N
OB J E T I VO: Caracterizar la tuberculosis (TB) en nin˜os
tratada con drogas de segunda lı´nea (SLD) en Lima,
Peru.
D I S E N˜O: Casos de TB en nin˜os reportados entre 2011 y
2015 en seis distritos de Lima. Se compararon los
resultados entre los menores de 5 an˜os y de 5 a 14 an˜os y
se evaluo´ el resultado del tratamiento.
R E SU LTADOS: De los 96 casos reportados, se evaluaron
a 82. De ellos, el 59% fueron varones, la edad media fue
de 8 an˜os y el 32% tenı´a menos de 5 an˜os. El contacto
con un caso ı´ndice de TB se notifico´ en el 82%; 90% no
tuvieron tratamiento previo, 98% tenı´a localizacio´n
pulmonar y 50% se sometieron a prueba de tuberculina,
con710 mm en el 88%. Se encontro´ un frotis positivo
en el 40%, todos en el grupo de 5 a 14 an˜os, y el 46%
tuvo un cultivo positivo. Solo el 26% tenı´a TB
multirresistente confirmada, de los cuales el 90%
tenı´an entre 5 y 14 an˜os. En todos los casos se usaron
SLD para tratar la TB confirmada o probablemente
resistente a drogas (TB-DR), obteniendo una alta
proporcio´n de e´xito (mayor al 83%), sin casos de falla
o muerte y una alta proporcio´n de pe´rdidas durante el
seguimiento.
CONC LU S I O´ N: La principal indicacio´n de SLD en la TB
en nin˜os fue el tratamiento empı´rico de la TB-DR debido
al contacto con uno o ma´s contactos con TB-DR. La
confirmacio´n bacteriolo´gica fue limitada, pero el e´xito
del tratamiento fue adecuado.
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